Dexmedetomidine Versus Propofol for Continuous Sedation in the Intensive Care Unit (ICU)
- Conditions
- Continuous Sedation in Initially Sedated Adults in ICU
- Interventions
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2010-08-13
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 500
- Registration Number
- NCT00479661
- Locations
- 🇷🇺
State Institution B.B. Petrovsky Russian Research Centre of Surgery of RAMS, 2, Abrikosovsky per., Moscow, Russian Federation
🇷🇺Medical Academy of Postgraduate Study, 41, ulica Kirochnaya,, St. Petersburg, Russian Federation
🇳🇱Westfries Gasthuis, Department Intensieve Zorgen, Maelsonstraat 3,, Hoorn, Netherlands
Study to Evaluate Initiation of Stalevo in Early Wearing-off
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 115
- Registration Number
- NCT00462007
- Locations
- 🇩🇪
Nervenarztpraxis Dr Alexander Nass, Köln, Germany
🇩🇪St. Josef-Hospital, Klinikum der Ruhr-Universität-Bochum Neurologische Klinik, Bochum, Germany
🇩🇪Humboldt Universität Charité Neurologische Klinik, Berlin, Germany
Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.
- Conditions
- Parkinson's Disease
- First Posted Date
- 2005-11-01
- Last Posted Date
- 2007-06-25
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 300
- Registration Number
- NCT00247247
- Locations
- 🇩🇪
Orion Pharma GmbH, Hamburg, Germany
Dexmedetomidine for Continuous Sedation
- Conditions
- Conscious Sedation
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2006-11-14
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 900
- Registration Number
- NCT00226785
- Locations
- 🇫🇮
Helsinki University Hospital, Helsinki, Finland
🇨🇭Inselspital, Bern, Switzerland
🇫🇮Kuopio University Hospital, Kuopio, Finland
Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients.
- Conditions
- Heart Failure
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT00219388
- Locations
- 🇸🇪
Cardiology Department, Sahlgrenska University Hospital, Gothenburg, Sweden
Peroral Levosimendan in Chronic Heart Failure
- Conditions
- Chronic Heart FailureHeart Diseases
- First Posted Date
- 2005-08-16
- Last Posted Date
- 2007-02-21
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 300
- Registration Number
- NCT00130884
- Locations
- 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass
- Conditions
- Coronary Heart Disease
- First Posted Date
- 2005-08-16
- Last Posted Date
- 2007-02-21
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT00130871
- Locations
- 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
🇫🇮Turku University Central Hospital, Turku, Finland
Stalevo in Early Wearing-Off Patients
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- Drug: Stalevo (levodopa/carbidopa/entacapone)Drug: Levodopa/carbidopa
- First Posted Date
- 2005-08-01
- Last Posted Date
- 2009-06-22
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 223
- Registration Number
- NCT00125567
- Locations
- 🇬🇧
Movement Disorder Services, Chertsey, Surrey, United Kingdom
🇬🇧University Hospital of Wales, Cardiff, Wales, United Kingdom
🇫🇮Tampere University Hospital, Tampere, Finland